Key Takeaways
- Record year, record quarter: FY22 revenue grew 45% YoY and Q4 grew 69% YoY, the highest ever, driven by capacity expansion and lithium-linked realisation gains.
- Lithium is a double-edged sword: Securing supply when competitors could not brought 20 new international customer inquiries and 5-6 approvals, but raw material price volatility compresses percentage margins even as absolute earnings rise.
- Margin guidance held flat despite the cycle: Management reiterated 18.5% EBITDA margin, +/-1%, choosing to absorb lithium cost pass-through lags and rising utility/logistics costs rather than chase near-term percentage expansion.
- FY24 revenue target set at Rs. 725-750 crore on a 'stable lithium price' assumption, with the caveat that if lithium stays elevated, revenue will overshoot; the new Rs. 150 crore CAPEX at Dahej unlocks Rs. 250-300 crore of incremental annual revenue potential.
- What to watch next quarter: Whether the 18-20 molecules readied for commercialisation translate into Dahej utilisation gains, the trajectory of lithium prices through uncharted territory, and any customer commitment that triggers a firm electrolyte CAPEX announcement.
Lithium: Supply Advantage, Price Risk & Pass-Through
- Supply secured when others failed: Neogen was able to source lithium while competitors, particularly those reliant on China, could not, keeping customers' production lines running and drawing 20 new international customer inquiries across the US, Europe, China, Japan and Korea.
- Customer approvals converting: 5-6 of those new international customers have been approved and started buying in the last 3-4 months, diversifying the customer base and providing a buffer against any demand impact from high prices.
- Price pass-through is working, with a lag: Most of the price increase has been passed on to customers so far, but the time lag between raw material cost absorption and realisation means percentage margins can compress while absolute EBITDA grows.
- Lithium is a small cost for many customers: For a large portion of the customer base, lithium is a very small component of the overall molecule, making the price increase manageable; for some traditional customers, the impact will be more difficult to absorb.
- Uncharted territory: Lithium prices in the next two quarters may reach 2-3x peak historical levels or 3-5x the 'stable' price baseline of calendar years 2017-2019, a scenario management has never navigated before.
Dr. Harin Kanani: "This is uncharted territory. Lithium prices have never gone so high, not by a close margin. It is going to be interesting for us to see."
Revenue Growth & the Dahej Ramp
- Q4 revenue of Rs. 156.8 crore was driven by capacity expansion initiatives and realisation gains for select products, though a slight QoQ moderation in Organic Chemicals reflected teething issues with new molecules manufactured at Dahej for the first time.
- The Rs. 500 crore near-miss: If a new molecule had stabilised and shipments started in March instead of April/May, FY22 revenue would have crossed Rs. 500 crore; the delay pushed that contribution into FY23.
- Dahej utilisation at 45-50% and climbing: The plant is slowly building up, and with existing customer demand now stabilised, capacity is being freed for new molecule trials and launches during the seasonally softer Q1 and Q2.
- 18-20 molecules in the commercialisation pipeline: Pilot work and R&D were completed last year on nearly two dozen molecules, creating a launch funnel that management expects to drive utilisation toward full levels by Q3, Q4, or certainly by next year.
- Advanced intermediates and CSM mix shift: The company targets advanced intermediates at 40% of revenue and CSM at 20% by FY24, up from CSM's current contribution of just over 10%, a shift that should improve gross margins even as manufacturing and fuel costs rise.
Dr. Harin Kanani: "At least, Neogen's customers are very happy that Neogen has lithium and their production has not stopped because Neogen is not able to supply lithium."
Margin Dynamics
- Q4 EBITDA margin of 17% was supported by higher utilisation and better product mix, but must be read against significant raw material price increases linked to lithium, higher utility costs, and logistical disruptions.
- Gross margin improvement absorbed by operating costs: Gross margins are improving because of the shift to advanced intermediates, but rising manufacturing costs, fuel, and transportation expenses keep EBITDA margin broadly flat.
- Operating leverage is not yet visible: A significant portion of operating costs were capitalised last year, so employee costs and other manufacturing overheads are not expected to decline meaningfully as a percentage of revenue in the near term.
- Lithium price pass-through lag creates a margin headwind: Because cost increases are passed on with a delay, percentage margins can show a decrease even as absolute EBITDA and PAT numbers continue to grow, a dynamic management flags as especially relevant this year.
- 18.5% EBITDA margin guidance held, +/-1%: Management explicitly declined to raise margin guidance despite the growth outlook, preferring to maintain the band and revisit the possibility of crossing 20% only after FY24, once newer businesses stabilise.
Dr. Harin Kanani: "Our absolute number will keep increasing, but when you look at percentage margin, it could show some decrease because of this lithium price. That is something which we will have to basically keep in mind especially this year."
CAPEX & Capacity Expansion
- Rs. 150 crore CAPEX approved for FY23 at Dahej SEZ, funded by a mix of equity from the preferential issue and additional debt, covering three distinct capacity additions.
- Specialty Organic Chemicals: Adding 60,000 litres of manufacturing capacity at Dahej SEZ, part of the brownfield expansion expected to complete by June 2023.
- Inorganic salts: Doubling capacity from 1,200 MT to 2,400 MT in the existing Inorganic MPP, driven by growing lithium salts demand.
- Lithium battery materials: Setting up a new 400 MTPA facility for Specialty Lithium Salts and Additives for Electrolyte used in Lithium-ion batteries, with equipment lead times pushing completion toward the later part of the CAPEX timeline.
- Incremental revenue potential of Rs. 250-300 crore per annum post-commissioning, with full utilisation of new capacities expected by FY25 or FY26 and an asset turn of approximately 2x.
- Electrolyte CAPEX for India remains uncommitted: Management is waiting for clarity and customer commitment before planning a facility that would need to be in thousands of metric tonnes to make economic sense, describing current investments as trial-scale.
Lithium-Ion Battery Strategy
- Electrolyte pilot plant progressing: Expected to be operational this year, serving as a trial investment to build capability before committing to commercial scale.
- Full backward integration intended: The plan is to do everything from lithium carbonate all the way up to electrolyte in-house, with lithium salts capacity kept slightly higher than captive needs to serve international market demand.
- Electrolyte and 400 MTPA lithium battery materials together are expected to generate about Rs. 150 crore in revenue at full utilisation on stable lithium prices.
- Sodium-ion not seen as a threat: Management does not expect sodium-ion battery technology to have a tremendous impact on plans, noting it is mostly considered for energy storage while the EV driver remains lithium-based; the battery materials produced could potentially also be used for sodium-ion systems.
- Revenue and investment breakup withheld: Management declined to share the exact CAPEX split or sales potential for the electrolyte and lithium salts businesses, citing the early stage and a desire not to mislead.
Balance Sheet & Working Capital
- Rs. 140 crore of the Rs. 225 crore preferential allotment has already been deployed toward the ongoing expansion programme.
- Working capital remains a trade-off with growth: Management acknowledged that the company has not yet been able to deliver both very high growth and strong cash generation simultaneously, and that improving this is a priority.
- Inventory rationalisation expected by FY24: Once Dahej reaches full utilisation and a higher percentage of revenue comes from dedicated molecules, inventory levels should become more manageable.
- Electrolyte and lithium contracts structured for lower working capital: The effort will be to set contracts in a way that minimises working capital requirements in these newer businesses.
- Blended tax rate expected at 19-22% going forward, supported by the higher contribution from the SEZ facility; management noted a broader range of 22-25% is also possible depending on the mix.
Dr. Harin Kanani: "So far, we have not been able to deliver both very high growth as well as cash. So we will keep improving on that."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Brownfield CAPEX completion | All expansions under the Rs. 150 crore CAPEX at Dahej SEZ completed | By June 2023 |
| Incremental revenue from brownfield | Rs. 250-300 crore per annum post-commissioning | Full utilisation by FY25/FY26 |
| FY24 revenue target | Rs. 725-750 crore, assuming stable lithium prices (2017-2019 levels); revenue will overshoot if lithium stays elevated | FY24 |
| EBITDA margin | Maintain 18.5%, +/-1%; revisit crossing 20% only after FY24 | Ongoing through FY24 |
| Revenue mix target | Advanced intermediates at 40% of revenue, CSM at 20% | By FY24 |
| Electrolyte pilot plant | Operational | This year (FY23) |
| Dahej full utilisation | Ramp through new molecule launches in Q1/Q2 | By Q3/Q4 FY23, certainly by next year |
| Blended tax rate | 19-22% (narrower range) or 22-25% (broader range) | Going forward |
| Electrolyte commercial CAPEX | Quantum in thousands of MT; announcement contingent on customer clarity and commitment | No timeline given |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue | ₹156.8 cr, +69% YoY |
| EBITDA | ₹26.6 cr, margin of 17% |
| PAT | ₹15.7 cr, +68% YoY |
| Organic Chemicals division growth | +38% YoY |
| Inorganic Chemicals division growth | +176% YoY |
| Domestic/export mix | 64% / 36% |
| Net Debt | ₹99 cr, vs ₹215 cr in previous year |
| Final dividend per share | ₹2.75 for FY22 |
| Board-approved CAPEX for FY23 | Up to ₹150 cr at Dahej SEZ |
| Incremental revenue potential from brownfield expansions | ₹250-300 cr per annum post commissioning, full utilisation by FY25/FY26 |
| Targeted revenue for FY24 | ₹725-750 cr |
| Dahej utilisation level | 45-50% |
| EBITDA margin guidance | 18.5%, +/-1% |
| Blended tax rate anticipated | 19-22% (CFO) to 22-25% (broader range per MD) |
| Asset turn for new CAPEX | ~2x, slightly lower than usual 2-2.5x |